Genmab — Director's Dealing 2016

Nov 11, 2016

Company Announcement

Copenhagen, Denmark; November 11, 2016 – In accordance with Article 19 of
Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,
the persons below have given Genmab A/S (Nasdaq Copenhagen: GEN) power of
attorney on their behalf to publish and report their trading in Genmab shares
and related instruments, as follows:

1. Details of the person discharging managerial responsibilities /
   person closely associated

---

a) Name Jan van de Winkel

2. Reason for the notification

a) Position/status President & Chief Executive
Officer

---

b) Initial notification/Amendment Initial notification

1. Details of the issuer, emission allowance market participant,
   auction platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for
   (i) each type of instrument; (ii) each type of transaction;
   (iii) each date; and (iv) each place where transactions have been conducted

---

a) Description of the financial Share
instrument, type of instrument DK0010272202
Identification code

---

b) Nature of the transaction Sale of shares

c) Price(s) and volume(s) Price(s) Volume(s)

                                       DKK 1,201.27                   17,500

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-11-11

f) Place of the transaction Nasdaq Copenhagen

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. A subcutaneous formulation of
ofatumumab is in development for relapsing multiple sclerosis. Daratumumab is
in clinical development for additional multiple myeloma indications and for
non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical
product pipeline. Genmab's technology base consists of validated and
proprietary next generation antibody technologies - the DuoBody® platform for
generation of bispecific antibodies, and the HexaBody® platform which creates
effector function enhanced antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 54
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark